Recent Updates in the Treatment of Myeloproliferative Neoplasms
In this segment, “Recent Updates in the Treatment of Myeloproliferative Neoplasms”, Srdan Verstovek, MD, PhD, and Laura Michaelis, MD, discuss emerging therapies and strategies for managing patients with MPNs.
Emerging agents for the treatment of high-risk essential thrombocythemia (ET) and polycythemia vera (PV) have shown potential to significantly improve outcomes. In myelofibrosis (MF), treatment selection and determining transplant eligibility remain complex and depend on individual patient and disease characteristics, which can be highly variable in this disease. New developments are on the horizon for the management of accelerated or blast-phase MPNs.